Category Archives: 1-Active/Enrolling

ImmuPharma/Orion (IPP-201101)

A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

 

DAIICHISANKYO PHARMA DEVELOPMENT (DS5565-A-E312)

 An open-label extension study of DS-5565 for 52 weeks in pain associated with Fibromyalgia.

 From widespread burning to localized stabbing, each sufferer experiences the pain associated with fibromyalgia differently. But one thing stays the same – the way that pain impacts on their day-to-day lives.

STARPHARMA (SLP7013-017)